Science & Pipeline
Lead Product.
DUO-207: A Next-Generation GEM/PTX Backbone
DUO-207 rebuilds gemcitabine and paclitaxel as a single, tumor-activated conjugate medicine. Multiple preclinical models confirm sustained levels of both active drugs in tumors with limited exposure of free drug in circulation. In short, DUO-207 transforms where, when, and for how long gemcitabine and paclitaxel remain active. This pharmacology opens a wide margin for safety and drives superior performance.
DUO-207’s chemistry sustains free, active GEM and PTX with half lives 10-14x longer in tumors than in circulation. DUO-207 given i.v. on days 1 and 15 to rats with large (>2cm dia.) pancreatic cancer xenograft tumors.
One product. One infusion. Lasting, coordinated tumor exposure.
Pharmacology drives efficacy, tolerability, and convenience.
By sustaining active GEM and PTX in tumors while limiting their time in circulation, DUO-207 is designed to improve treatment across three dimensions.
Robust efficacy: DUO-207 consistently controls tumor growth, outperforming separately administered GEM+PTX in patient and murine tumor models,
Improved tolerability: Small and large animals treated with clinical relevant doses of DUO-207, but not free GEM+PTX, maintained favorable body-weights
Less frequent, simpler dosing: DUO-207’s extended half-life allows dosing once every two or three weeks, compared with the three times per 28-day cycle commonly used for GEM + nab-paclitaxel.
DUO-207 (yellow) halts the growth of human derived tumors that remain unchecked by standard of care (light blue). Negative control is shown in dark blue.